STP125G is a single-stranded siRNA therapeutics targeting ApoC3 mRNA, based on Sirnaomics proprietary GalAheadTM mxRNA technology.... Jul 24
Surgery is currently the most common treatment option for the treatment of NMSC which often carry significant cutaneous adverse events, risk of scar, infection, bleeding ... Apr 27
The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA... Jan 18
The primary endpoint of this trial was to evaluate patients for complete histological clearance of the tumour cells within the treated isSCC lesion... Dec 21
-Advertisements-